June 6, 2018
Study: Medical device tax hurts investment in R&D
Editor's Note:
This study from Iowa State University shows companies have cut funding for research and development (R&D) in response to the medical device tax imposed by the Affordable Care Act.
Since 2013, the 2.3% excise tax has significantly reduced:
- R&D investment by $34 million
- Sales revenue by $188 million
- Gross margins by $375 million
- Earnings by $68 million.
The study, which is the first to look at the actual cost of the tax on manufacturers, found it also affected operating and marketing costs.
Free Daily News
- Study: Cataract surgery increases diabetic retinopathy progression
- FDA announces Class 1 endovascular system, anesthesia system recalls
- Cost-shifting concerns rise as GOP eyes Medicaid cuts
- Study: Prolonged general anesthesia linked to long-term cognitive decline
- Real-time cancer detection improves brain surgery precision
- Research highlights anesthesia provider knowledge gap on drug, hormonal contraceptive interactions
- Healthcare CFOs prioritize cost control, data-driven decisions
- Study links intraoperative synthetic opioids, worse postoperative pain
- Tooth-in-eye surgery offers hope for restored vision
- Tenet Healthcare's strategic ASC expansion, hospital divestitures boost 2024 Q4 results
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement